Skip to main content
Fig. 2 | BMC Women's Health

Fig. 2

From: Gonadotropin-releasing hormone agonist for the preservation of ovarian function in survivors of haematopoietic stem cell transplantation for haematological diseases

Fig. 2

The difference between the GnRH-a treated or untreated patients regarding POI rate in survivors did not reach statistical significance after subgroup analysis based on whether received conventional chemotherapy prior to myeloablative regimen for HSCT (A) or not (B). POI, premature ovarian insufficiency; COF, cyclic ovarian function

Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us